[Clinical developments for the EGFR-TKI combined with radiotherapy in advanced non-small cell lung cancer]

Area of Science:

• Oncology
• Medical Physics

Background:

• Lung cancer is a leading cause of cancer death worldwide.
• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective targeted therapies for EGFR-mutated stage IV non-small cell lung cancer (NSCLC).
• Acquired resistance to EGFR-TKIs is a significant clinical challenge in advanced NSCLC treatment.

Purpose of the Study:

• To review the current research on the combination of EGFR-TKIs and radiotherapy for advanced NSCLC.
• To explore the potential of combined EGFR-TKI and radiation therapy in overcoming drug resistance.

Main Methods:

• Literature review of preclinical studies and clinical trials.
• Analysis of research investigating the synergistic effects of EGFR-TKIs and ionizing radiation.
• Discussion of treatment strategies for advanced NSCLC.

Main Results:

• Preclinical studies indicate that EGFR-TKIs can potentiate the antitumor effects of ionizing radiation.
• The combination therapy shows promise in preclinical models for overcoming acquired resistance to EGFR-TKIs.
• EGFR-TKI and radiotherapy combination is a promising therapeutic strategy for advanced NSCLC.

Conclusions:

• The combination of EGFR-TKIs and radiotherapy presents a highly promising therapeutic approach for advanced NSCLC.
• This combined modality may offer a strategy to overcome acquired resistance to targeted therapy.
• Further clinical investigation is warranted to establish the efficacy and safety of this combination therapy.